トラニルシプロミン 化学特性,用途語,生産方法
効能
抗うつ薬, モノアミン酸化酵素(MAO)阻害薬
世界保健機関（WHO）
Tranylcypromine, a monoamine oxidase inhibitor (MAOI), was
introduced in 1961 for the treatment of depressive illness. By 1964 its use had been
associated with transient hypertensive crises and other adverse effects when taken
together with certain cheeses and other foods containing tyramine. This led to the
withdrawal of the drug in several countries and the suspension of marketing on a
worldwide basis by the major manufacturer pending review of these adverse
reactions. Subsequently, in response to requests from the medical profession,
tranylcypromine was resubmitted for registration with appropriate warnings in the
product information and it is now marketed in more than 30 countries.
トラニルシプロミン 上流と下流の製品情報
原材料
準備製品